A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
Trial Details
- NCT ID
- NCT06756321
- Phase
- EARLY_PHASE1
- Sponsor
- Affiliated Hospital of Nantong University
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
- Fludarabine
- Cyclophosphamide
- Locations (sample)
- Nantong, Jiangsu, China|32.03028,120.87472
Key Eligibility Criteria
- Patients must meet all of the following criteria to be eligible for the study:
- Voluntarily participate in the clinical study. The individual or the legal guardian fully understands the study, sign the informed consent form (IC…
- Age ≥ 18 years and \< 70 years.
- Subjects with refractory or relapsed disease after current standard treatments (including allogeneic or autologous hematopoietic stem cell transpla…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →